Drug Profile


Alternative Names: ACTH RF; Corticoliberin; Corticotrophin-releasing hormone; Corticotropin-releasing factor; hCRF; Human corticotropin-releasing hormone; NEU 3002; Ovine corticotrophin-releasing factor; Xerecept

Latest Information Update: 02 Sep 2015

Price : $50

At a glance

  • Originator Salk Institute
  • Developer Celtic Pharma
  • Class Pituitary hormone releasing hormones
  • Mechanism of Action Corticotropin-releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain oedema
  • New Molecular Entity No

Highest Development Phases

  • No development reported Brain oedema; Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 02 Sep 2015 No recent reports on development identified - Phase-I/II for Brain oedema (In adolescents, In children) in USA (SC)
  • 02 Sep 2015 No recent reports on development identified - Preclinical for Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top